drugset / Trial / NCT00428584

RNF and Betaseron® Tolerability Study

NCT00428584

Phase 3 Completed 129 enrolled EMD Serono Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.

Timeline

Start
2006-12
Primary completion
2007-11
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Interferon beta-1b Protein / enzyme biologic 250 ug Subcutaneous
Subject human interferon beta 1a Unknown 44 ug Subcutaneous